TriSalus Life Sciences (TLSI) Common Equity (2022 - 2025)
Historic Common Equity for TriSalus Life Sciences (TLSI) over the last 4 years, with Q3 2025 value amounting to -$26.7 million.
- TriSalus Life Sciences' Common Equity fell 3078.69% to -$26.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$26.7 million, marking a year-over-year decrease of 3078.69%. This contributed to the annual value of -$25.9 million for FY2024, which is 432.66% up from last year.
- According to the latest figures from Q3 2025, TriSalus Life Sciences' Common Equity is -$26.7 million, which was down 3078.69% from -$19.4 million recorded in Q2 2025.
- In the past 5 years, TriSalus Life Sciences' Common Equity ranged from a high of $8.5 million in Q3 2023 and a low of -$198.4 million during Q2 2023
- For the 4-year period, TriSalus Life Sciences' Common Equity averaged around -$53.4 million, with its median value being -$25.9 million (2024).
- Examining YoY changes over the last 5 years, TriSalus Life Sciences' Common Equity showed a top increase of 17279.25% in 2023 and a maximum decrease of 161858.64% in 2023.
- Over the past 4 years, TriSalus Life Sciences' Common Equity (Quarter) stood at -$176.3 million in 2022, then soared by 84.65% to -$27.1 million in 2023, then rose by 4.33% to -$25.9 million in 2024, then dropped by 3.21% to -$26.7 million in 2025.
- Its Common Equity stands at -$26.7 million for Q3 2025, versus -$19.4 million for Q2 2025 and -$34.4 million for Q1 2025.